The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 2 of the 27 sources its claims cite were checked for support.
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
Open accessAbstract
Summary Background A severe form of encephalitis associated with antibodies against NR1–NR2 heteromers of the NMDA receptor was recently identified. We aimed to analyse the clinical and immunological features of patients with the disorder and examine the effects of antibodies against NMDA receptors in neuronal cultures. Methods We describe the clinical characteristics of 100 patients with encephalitis and NR1–NR2 antibodies. HEK293 cells ectopically expressing single or assembled NR1–NR2 subunits were used to determine the epitope targeted by the antibodies. Antibody titres were measured with ELISA. The effect of antibodies on neuronal cultures was determined by quantitative analysis of NMDA-receptor clusters. Findings Median age of patients was 23 years (range 5–76 years); 91 were women. All patients presented with psychiatric symptoms or memory problems; 76 had seizures, 88 unresponsiveness (decreased conciousness), 86 dyskinesias, 69 autonomic instability, and 66 hypoventilation. 58 (59%) of 98 patients for whom results of oncological assessments were available had tumours, most commonly ovarian teratoma. Patients who received early tumour treatment (usually with immunotherapy) had better outcome (p=0.004) and fewer neurological relapses (p=0.009) than the rest of the patients. 75 patients recovered or had mild deficits and 25 had severe deficits or died. Improvement was associated with a decrease of serum antibody titres. The main epitope targeted by the antibodies is in the extracellular N-terminal domain of the NR1 subunit. Patients’ antibodies decreased the numbers of cell-surface NMDA receptors and NMDA-receptor clusters in postsynaptic dendrites, an effect that could be reversed by antibody removal. Interpretation A well-defined set of clinical characteristics are associated with anti-NMDA-receptor encephalitis. The pathogenesis of the disorder seems to be mediated by antibodies.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This case series characterizes 100 patients with anti-NMDA-receptor encephalitis and shows that antibodies target the extracellular N-terminal domain of NR1, reduce cell-surface NMDA receptors and postsynaptic receptor clusters, and that early tumour treatment is associated with better outcome and fewer relapses. The disorder is severe but often reversible, with 75 patients recovering or having mild deficits and 25 having severe deficits or dying.
Key findings
- Among 100 patients, median age was 23 years (range 5–76) and 91 were women; all presented with psychiatric symptoms or memory problems, 76 had seizures, 88 unresponsiveness, 86 dyskinesias, 69 autonomic instability, and 66 hypoventilation.
- 58 (59%) of 98 assessed patients had tumours, most commonly ovarian teratoma; early tumour treatment was associated with better outcome (p=0.004) and fewer neurological relapses (p=0.009) than in other patients.
- 75 patients recovered or had mild deficits and 25 had severe deficits or died; improvement was associated with a decrease in serum antibody titres.
- Patients’ antibodies mainly targeted the extracellular N-terminal domain of NR1 and decreased cell-surface NMDA receptors and NMDA-receptor clusters in postsynaptic dendrites, an effect reversed by antibody removal.
Methods
- Observational case series of 100 patients with encephalitis and NR1–NR2 antibodies; clinical information was obtained by authors or referring physicians, with control samples from 20 healthy individuals and 230 patients with suspected autoimmune or paraneoplastic encephalitis or tumours without encephalitis.
- HEK293 cells expressing single or assembled NR1–NR2 subunits were used to map the antibody epitope; antibody titres were measured by ELISA, and effects on neuronal cultures were assessed by quantitative confocal analysis of NMDA-receptor clusters and by biotinylation/immunoblot of cell-surface NR1.
- Statistical analyses used Fisher’s two-sided exact test, Kruskal-Wallis and Wilcoxon rank-sum tests with Bonferroni correction, and Kruskal-Wallis non-parametric ANOVA with Dunn’s pairwise comparison.
Limitations
- The paper states that follow-up CSF titres were not obtained in most patients after improvement, and that future studies should clarify the best type and duration of immunotherapy, the role of prodromal events, and the molecular mechanisms decreasing NMDA receptors.
- Evident from the text: this is an observational case series without randomized treatment allocation, so associations between early tumour treatment and outcome may be confounded; some clinical and laboratory data are reported as “data not shown.”
- Evident from the text: the pathogenic evidence relies partly on in-vitro rat hippocampal neuronal cultures and HEK293 assays, which may not fully capture human disease mechanisms.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
70 Own result · 13 Not checked yet · 13 Own interpretation · 1 Supported · 1 Partly supported · 1 Own method · accuracy not yet measured
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All patients presented with psychiatric symptoms or memory problems; 76 had seizures, 88 unresponsiveness (decreased conciousness), 86 dyskinesias, 69 autonomic instability, and 66 hypoventilation.”
- Also stated in: § Results · plain
“During the first 3 weeks of symptom presentation, 76 patients had seizures.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Abstract > Findings
plainn = 76- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Median age of patients was 23 years (range 5–76 years); 91 were women.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Abstract > Findings
plainn = 100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Median age of patients was 23 years (range 5–76 years); 91 were women.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Abstract > Findings
plainn = 100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All patients presented with psychiatric symptoms or memory problems; 76 had seizures, 88 unresponsiveness (decreased conciousness), 86 dyskinesias, 69 autonomic instability, and 66 hypoventilation.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Abstract > Findings
plainn = 100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“92 patients had extensive EEG monitoring, 77% had generalised or predominantly frontotemporal slow or disorganised activity (delta-theta) without epileptic discharges.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 92- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“20 (27%) had prominent sleep dysfunction, including hypersomnia and inversion of sleep patterns.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 75- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“23 presented with short-term memory loss or seizures alone or associated with psychiatric manifestations.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainstates an associationn = 23- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of hospitalisation was 2.5 months (range 1–14 months).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In six patients, the tumour was diagnosed after recovery from the encephalitis (56–380 months).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The main epitope targeted by the antibodies is in the extracellular N-terminal domain of the NR1 subunit.”
- Also stated in: § Results · plain
“Hence the main epitope region recognised by all patients’ antibodies lies within the extracellular region of the NR1 subunit (webtable 3).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Abstract > Findings
plainn = 92- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
- Probably not a substantial claim. 8
- It may state two separate claims as one. 30
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Partly supportedcites [2] Coyle, 2006, Glutamate and schizophrenia: beyond the dopamine hypothesis, Cell Mol Neurobiol sourceExperimental — accuracy not yet measured
The Introduction says excessive activation of extrasynaptic NMDA receptors can cause oxidative stress and neuronal death, supporting the excitotoxicity mechanism. It does not link that mechanism to epilepsy, dementia, or stroke (searched each condition). The paper also discusses NMDA-receptor hypofunction in schizophrenia, but that does not establish the three disease-specific links in the quoted claim. (LLM, conf=0.87)
- Not checked yetcites [3] Waxman, 2005, N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease, Neuroscientist source
- Not checked yetcites [4] Lau, 2007, NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders, Nat Rev Neurosci source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Serum and CSF were tested for antibodies against the NMDA receptor,5 and considered positive if three immunohistochemical criteria were fulfilled (figure 1).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Methods > Patients and procedures
What the sources say
- Supportedcites [5] Dalmau, 2007, Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma, Ann Neurol source
The citation follows the statement that serum and CSF were tested for NMDA-receptor antibodies. The Immunocytochemistry passage describes testing both sample types, and the Results report their reactivity with NMDA-receptor heteromers. The three-criteria rule follows the citation and is not attributed to this source. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One boy (11 years old, without tumour) and 21 women and girls were younger than 19 years (median 15 years, range 5–18 years); 12 had an ovarian teratoma (five with immature features), and nine had no tumour.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 21- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“14 patients had brain biopsy: findings for two were normal, 12 showed mild perivascular lymphocytic cuffng, and ten microglial activation.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 14- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time from symptom presentation to initial signs of improvement was 8 weeks (range 2–24 weeks) for the group of patients with early tumour treatment, 11 weeks (4–40 weeks) for the group whose tumour was treated late or not treated, and 10 weeks (2–50 weeks) for the group without tumour (Kruskal-Wallis, p=0.10)”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All had negative results for neuronophagic nodules and viral assays.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 14- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“37 patients had cardiac dysrhythmias, including tachycardia or bradycardia, with prolonged pauses in seven patients; four needed pacemakers.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 37- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While hospitalised, seven patients had high levels of serum creatine kinase, six developed pulmonary embolism, six transient aphasia, four hemiparesis, and four tetraparesis.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Median follow-up was 17 months (1–194 months): 47 patients had full recovery, 28 mild stable deficits, 18 severe deficits, and seven died as a result of the neurological disorder.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 47- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“52 patients had dyskinesias, autonomic instability, and hypoventilation, 27 patients had two of these symptoms, and 14 had just one; the remaining seven patients developed a milder syndrome of seizures and psychiatric symptoms.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 52- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All teratomas contained nervous tissue; 25 were examined for expression of NMDA receptors, and all were positive (data not shown).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Eight patients had bilateral teratomas; four were synchronous, two had history of a contralateral teratoma, and two developed contralateral teratomas before recurrence of the encephalitis.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 8- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These findings were limited to a single area of the brain in 19 patients: 16 had abnormalities in medial temporal lobes, two in the corpus callosum, and one in the brainstem.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainn = 19- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients who improved had a parallel decrease of serum titres, whereas those who did not improve maintained high titres in CSF and serum (figure 3).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Relapses were less common in patients with early tumour treatment (1 of 36) than in other patients (14 of 64; p=0.009), including patients whose tumour was treated late (six of 22; p=0.009) and patients without tumour (eight of 42; p=0.03).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our study indicates that 41% of patients with anti-NMDA-receptor encephalitis do not have a clinically detectable tumour, and that men and children can also be affected.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Discussion
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Four patients who died and whose CSF was available were among the group with the highest titres, whereas the seven patients with milder syndromes had the lowest titres (data not shown).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainstates an associationn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The use of these heteromers abrogated the reactivity of sera or CSF from 92 patients’, and substantially decreased the reactivity of the samples of the remaining eight cases.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plainstates a causen = 92- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While poorly responsive or in a catatonic-like state, 93 patients developed hypoventilation, autonomic imbalance, or abnormal movements, all overlapping in 52 patients.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Discussion
plainstates an associationn = 93- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Analysis of the reactivity of patients’ sera or CSF against the indicated NMDA-receptor subunits or heteromers showed that antibody reactivity was not modified by changing the NR2 subunit (A, B, C, or D) and was retained by homomers of NR1 (webtable 3).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The receptors are heteromers of NR1 subunits that bind glycine and NR2 (A, B, C, or D) subunits that bind glutamate.1”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Not checked yetcites [1] Lynch, 1994, N-methyl-D-aspartate receptors: different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents, Mol Pharmacol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Preliminary studies suggested the target epitopes were located in extracellular regions of NR1–NR2B NMDA receptors.5”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Not checked yetcites [5] Dalmau, 2007, Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma, Ann Neurol source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Despite the severity of the disorder, patients often recovered after tumour removal and immunotherapy, suggesting an immune-mediated pathogenesis.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Not checked yetcites [5] Dalmau, 2007, Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma, Ann Neurol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“NMDA receptors are ligand-gated cation channels with crucial roles in synaptic transmission and plasticity.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Not checked yetcites [1] Lynch, 1994, N-methyl-D-aspartate receptors: different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents, Mol Pharmacol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All patients had brain MRI, radiological screening for a systemic neoplasm, and serological or CSF studies that ruled out other disorders (webappendix).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Methods > Patients and procedures
plainn = 21- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Not checked yetcites [2] Coyle, 2006, Glutamate and schizophrenia: beyond the dopamine hypothesis, Cell Mol Neurobiol source
- Not checked yetcites [3] Waxman, 2005, N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease, Neuroscientist source
- Not checked yetcites [4] Lau, 2007, NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders, Nat Rev Neurosci source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The first patients identified were young women with ovarian teratoma who presented with psychosis or memory problems, rapidly progressing to multiple neurological deficits requiring prolonged intensive care support.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Not checked yetcites [5] Dalmau, 2007, Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma, Ann Neurol source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“We recently identified a disorder, designated anti-NMDA-receptor encephalitis, that associates with antibodies against NR1–NR2 heteromers and results in a characteristic neuropsychiatric syndrome.5”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Introduction
What the sources say
- Not checked yetcites [5] Dalmau, 2007, Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma, Ann Neurol source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Neurological outcome was assessed with the modified Rankin scale (MRS)10 and mini-mental state examination (MMSE).11”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Methods > Patients and procedures
What the sources say
- Not checked yetcites [10] van Swieten, 1988, Interobserver agreement for the assessment of handicap in stroke patients, Stroke source
- Not checked yetcites [11] Folstein, 1975, “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The latter effect was reversed by removing the antibodies from the cultures, explaining the potential reversibility of patients’ symptoms.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Discussion
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Anti-NMDA-receptor encephalitis represents a new category of immune-mediated disorder that is often paraneoplastic, treatable, and can be diagnosed serologically.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Discussion
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, although the presence of a tumour that expresses NMDA receptors likely contributes to breaking immune tolerance, other unknown immunological triggers seem to be involved.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Discussion
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Recovery from this disorder is typically slow, and symptoms may relapse, especially in patients with undetected or recurrent tumours and patients with no associated tumours.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Discussion
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A pathogenic role of patients’ antibodies is suggested by the correlation between antibody titres and neurological outcome and by the decrease in number of postsynaptic clusters of NMDA receptors caused by patients’ antibodies.”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Discussion
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The effects of patients’ antibodies on rat hippocampal neuronal cultures reflect the effects of those antibodies on human neurons in anti-NMDA-receptor encephalitis.
“To assess the effect of patients’ antibodies on neuronal cultures, we first determined the extent of immunolabelling of NR1 (or NMDA receptor) clusters in postsynaptic dendrites.”
The paper relies on this without support.
HEK293 cells ectopically expressing recombinant NR1 or NR1–NR2B subunits present the same epitopes as native NMDA receptors for patients’ antibodies.
“Antibody titres were measured with ELISA on HEK293 cell lysates ectopically expressing NR1 or NR1–NR2B heteromers (webappendix).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Psychotomimetic models (eg, models that mimic the symptoms of psychosis), especially those based on ketamine (an antagonistic agent of NMDA-R), also support the E/I imbalance hypothesis.”
From Are hallucinations due to an imbalance between excitatory and inhibitory influences on the brain? (2016) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients usually present with acute behavioral change, psychosis and catatonia that evolve to include seizures, memory deficit, dyskinesias, speech problems, and autonomic and breathing dysregulation.3”
From Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study (2013) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“If a tumor is found, removal is important because it expedites improvement and decreases relapses.3, 17”
From Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study (2013) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Samples were considered positive if they fulfilled previously reported criteria3 including (1) a characteristic pattern of immunostaining of the neuropil of rat brain, and (2) specific reactivity with HEK293 cells expressing GluN1 (also known as NR1) subunits of the NMDAR.”
From Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study (2013) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The disorder, named “anti-NMDAR encephalitis”, has since been recognized in patients of all ages, but more frequently in young adults and children with or without teratoma.3, 4”
From Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study (2013) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Despite the severity of the disease, patients often improve after intensive care support, immunotherapy, and prolonged hospitalizations that require multidisciplinary care.3, 11”
From Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study (2013) · cites this paper as [3]
In the citing paper
“Recently, autoimmune diseases associated with anti-NMDAR antibodies were reported to be associated with severe psychosis 14 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
“All but one of these patients developed neurological symptoms before the tumour diagnosis (median 8 weeks, range 1–380 weeks).”
§ Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies > Results
“In six patients, the tumour was diagnosed after recovery from the encephalitis (56–380 months).”
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Paraneoplastic anti– N ‐methyl‐ D ‐aspartate receptor encephalitis associated with ovarian teratoma
Dalmau, J., Tüzün, E., Wu, H., Masjuan, J., Rossi, J. E., Voloschin, A., Baehring, J. M., Shimazaki, H., Koide, R., King, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21050 · Cited by 2,492
Self-citationB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders
Lau, C. G., & Zukin, R. S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2153 · Cited by 1,159
Tibbling, G., Link, H., & Ohman, S. (1977) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365517709091496 · Cited by 971
Cited by
Sorted by citations
Items 601–700 of 1,002
Anti-neuronal autoantibodies: Current diagnostic challenges
Probst, C., Saschenbrecker, S., Stoecker, W., & Komorowski, L. (2013) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2013.12.001 · Cited by 42
Kruse, J. L., Jeffrey, J. K., Davis, M. C., Dearlove, J., IsHak, W. W., & Brooks, J. O. (2014) · Annals of Clinical Psychiatry · doi:10.1177/104012371402600205 · Cited by 42
Wright, S. K., Geerts, A. T., der Zijde, C. M. J., Jacobson, L. W., Lang, B., Waters, P. J., van Tol, M. J. D., Stroink, H., Neuteboom, R. F., Brouwer, O. F., et al. (2016) · Epilepsia · doi:10.1111/epi.13356 · Cited by 42
Electroconvulsive Therapy in Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Coffey, M. J., & Cooper, J. J. (2016) · Journal of Ect · doi:10.1097/yct.0000000000000334 · Cited by 44
Li, Y., Viscidi, R. P., Kannan, G., McFarland, R., Pletnikov, M. V., Severance, E. G., Yolken, R. H., & Xiao, J. (2018) · Infection and Immunity · doi:10.1128/iai.00398-18 · Cited by 42
Diagnostic challenges in rapidly progressive dementia
Zerr, I., & Hermann, P. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1519397 · Cited by 44
A systematic review of Gamma-aminobutyric Acid Receptor Type B autoimmunity
McKay, J. H., Dimberg, E. L., & Lopez-Chiriboga, A. S. (2018) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2018.0005 · Cited by 42
Wickham, J., Corna, A., Schwarz, N., Uysal, B., Layer, N., Honegger, J. B., Wuttke, T. V., Koch, H., & Zeck, G. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00283 · Cited by 42
Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy
Celli, R., & Fornai, F. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200831154658 · Cited by 43
Serafini, A., Lukas, R. V., VanHaerents, S. A., Warnke, P. C., Tao, J. X., Rose, S., & Wu, S. (2016) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.04.046 · Cited by 42
Lim, M. J., Hacohen, Y., & Vincent, A. C. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2015.03.011 · Cited by 43
Autoimmune Encephalitis—Misdiagnosis, Misconceptions, and How to Avoid Them
Dalmau, J. O., & Graus, F. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.4154 · Cited by 42
Self-citationCurrent and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology
Ismail, F. S., Gallus, M., Meuth, S. G., Okada, H., Hartung, H.-P., & Melzer, N. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3818 · Cited by 41
Neuropsychiatric Autoimmune Encephalitis without VGKC-Complex, NMDAR, and GAD Autoantibodies
Najjar, S., Pearlman, D. M., Devinsky, O., Najjar, A., Nadkarni, S. S., Butler, T., & Zagzag, D. (2013) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0b013e31828b6531 · Cited by 42
Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid
Asgari, N., Khorooshi, R., Lillevang, S. T., & Owens, T. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.09.010 · Cited by 41
Kiani, R., Lawden, M., Eames, P. J., Critchley, P., Bhaumik, S., Odedra, S., & Gumber, R. (2015) · BJPsych Bulletin · doi:10.1192/pb.bp.112.041954 · Cited by 41
Schmitt, A., Martins‐de‐Souza, D., Akbarian, S., Cassoli, J. S., Ehrenreich, H., Fischer, A., Fonteh, A. N., Gattaz, W. F., Gawlik, M., Gerlach, M., et al. (2016) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1224929 · Cited by 43
Haberlandt, E., Ensslen, M., Gruber‐Sedlmayr, U., Plecko, B., Brunner‐Krainz, M., Schimmel, M., Schubert‐Bast, S., Neirich, U., Philippi, H., Kurleman, G., et al. (2016) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2016.11.016 · Cited by 41
Yang, X., Zhu, H., Ren, H., Zhu, Y., Peng, B., Cui, L., & Guan, H. (2018) · Chinese Medical Journal · doi:10.4103/0366-6999.222327 · Cited by 41
Anti-N-methyl-d-aspartate receptor encephalitis in children: Incidence and experience in Hong Kong
Ho, A. C.-C., Chan, H. S., Chan, E. S. Y., Wong, S. S.-N., Fung, S., Cherk, S. W. W., Fung, E. L.-W., Ma, K.-H., Tsui, K.-W., Yau, E. K., et al. (2018) · Brain and Development · doi:10.1016/j.braindev.2018.02.005 · Cited by 41
Anti-N-Methyl d-Aspartate Receptor Encephalitis and Electroconvulsive Therapy
Tanguturi, Y. C., Cundiff, A. W., & Fuchs, C. (2018) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2018.07.005 · Cited by 41
Chang, C.-H., Lin, C., Liu, C., Chen, S.-J., & Lane, H. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120908016 · Cited by 42
Clinically based score predicting cryptogenic NORSE at the early stage of status epilepticus
Yanagida, A., Kanazawa, N., Kaneko, J., Kaneko, A., Iwase, R., Suga, H., Nonoda, Y., Onozawa, Y., Kitamura, E., Nishiyama, K., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000849 · Cited by 41
Primary and Secondary Central Nervous System Vasculitis
Gowdie, P. J., Twilt, M., & Benseler, S. M. (2012) · Journal of Child Neurology · doi:10.1177/0883073812459352 · Cited by 41
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_310395 · Cited by 41
Titulaer, M. J., Leypoldt, F., & Dalmau, J. O. (2013) · Movement Disorders · doi:10.1002/mds.25716 · Cited by 40
Self-citationOvarectomy despite Negative Imaging in Anti-NMDA Receptor Encephalitis: Effective Even Late
Boeck, A.-L., Logemann, F., Krauß, T., Hussein, K., Bültmann, E., Trebst, C., & Stangel, M. (2013) · Case Reports in Neurological Medicine · doi:10.1155/2013/843192 · Cited by 40
Update on Paraneoplastic Neurologic Disorders
Rosenfeld, M. R., & Dalmau, J. O. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0001 · Cited by 40
Self-citationLimbic encephalitis associated with anti-NH2-terminal of α-enolase antibodies
Kishitani, T., Matsunaga, A., Ikawa, M., Hayashi, K., Yamamura, O., Hamano, T., Watanabe, O., Tanaka, K., Nakamoto, Y., & Yoneda, M. (2017) · Medicine · doi:10.1097/md.0000000000006181 · Cited by 40
Anti-neuronal anti-bodies in patients with early psychosis
Mantere, O., Saarela, M., Kieseppä, T., Raij, T. T., Mäntylä, T. J. S., Lindgren, M., Rikandi, E., Stoecker, W., Teegen, B., & Suvisaari, J. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.04.027 · Cited by 40
Immunotherapy for anti-NMDA receptor encephalitis: Experience from a single center in Taiwan
Kong, S., Chen, Y., Su, I.-C., Lin, J., Chou, I., Chou, M.-L., Hung, P., Hsieh, M., Wang, Y., Chou, C., et al. (2018) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2018.10.006 · Cited by 40
Long‐term cognitive and neuropsychiatric outcomes in patients with anti‐NMDAR encephalitis
Liu, X., Zhang, L., Chen, C., Gong, X., Lin, J., An, D., Zhou, D., & Hong, Z. (2019) · Acta Neurologica Scandinavica · doi:10.1111/ane.13160 · Cited by 40
Understanding Childhood Neuroimmune Diseases of the Central Nervous System
Matricardi, S., Farello, G., Savasta, S., & Verrotti, A. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00511 · Cited by 40
Hansen, N., & Timäus, C. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02258-z · Cited by 41
Targeting NMDA Receptor Complex in Management of Epilepsy
Sivakumar, S., Ghasemi, M., & Schachter, S. C. (2022) · Pharmaceuticals · doi:10.3390/ph15101297 · Cited by 40
Update on paraneoplastic neurological syndromes
Didelot, A., & Honnorat, J. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283306647 · Cited by 40
Fleischmann, R., Prüß, H., Rosche, B., Bahnemann, M., Gelderblom, H., Deuschle, K., Harms, L., Kopp, U. A., & Ruprecht, K. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1817 · Cited by 40
NMDA receptors are expressed in human ovarian cancer tissues and human ovarian cancer cell lines
North, W. G., Liu, F., Tian, R., Abbasi, H., & Akerman, B. L. (2015) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s90367 · Cited by 43
Long term rehabilitation management and outcome of anti-NMDA receptor encephalitis: Case reports
Bach, L. J. (2014) · Neurorehabilitation · doi:10.3233/nre-141176 · Cited by 40
Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome
Panzer, J. A., Anand, R., Dalmau, J. O., & Lynch, D. R. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.07.007 · Cited by 39
Self-citationPediatric Anti-NMDA (N-methyl D-Aspartate) Receptor Encephalitis
Salvucci, A. E., Devine, I. M., Hammond, D. N., & Sheth, R. D. (2014) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2014.01.012 · Cited by 39
The LGI1–ADAM22 protein complex in synaptic transmission and synaptic disorders
Fukata, Y., Yokoi, N., Miyazaki, Y., & Fukata, M. (2016) · Neuroscience Research · doi:10.1016/j.neures.2016.09.011 · Cited by 39
Gordon‐Lipkin, E. M., Yeshokumar, A. K., Saylor, D. R., Arenivas, A., & Probasco, J. C. (2017) · Journal of Child Neurology · doi:10.1177/0883073817720340 · Cited by 39
Scharf, M., Miske, R., Kade, S., Hahn, S., Denno, Y., Begemann, N., Rochow, N., Radzimski, C., Brakopp, S., Probst, C., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01447 · Cited by 39
Zhang, W., Wang, X., Shao, N., Ma, R., & Meng, H. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.10.038 · Cited by 39
Contemporary advances in anti-NMDAR antibody (Ab)-mediated encephalitis
Seery, N., Butzkueven, H., O'Brien, T. J., & Monif, M. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103057 · Cited by 39
Relapses of Anti-NMDAR, Anti-GABABR and Anti-LGI1 Encephalitis: A Retrospective Cohort Study
Zhong, R., Chen, Q., Zhang, X., Zhang, H., & Lin, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.918396 · Cited by 39
Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies
Alexopoulos, H., Kosmidis, M. L., Dalmau, J. O., & Dalakas, M. C. (2011) · Journal of Neurology · doi:10.1007/s00415-011-5982-4 · Cited by 39
Self-citationAnti-NMDA receptor encephalitis after TdaP–IPV booster vaccination: cause or coincidence?
Hofmann, C., Baur, M.-O., & Schroten, H. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5757-3 · Cited by 39
Immune-related encephalitis after immune checkpoint inhibitor therapy
Buckley, M. W., Balaji, A., Brahmer, J. R., Cappelli, L. C., Sharfman, W. H., Fuchs, E. J., Kang, H., Forde, P. M., Gladstone, D. E., Ambinder, R. F., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae186 · Cited by 38
Neuro-immunobiology and treatment assessment in a mouse model of anti-NMDAR encephalitis
Maudes, E., Planagumà, J., Marmolejo, L., Radosevic, M., Serafim, A. B., Aguilar, E., Sindreu, C. B., Landa, J., García‐Serra, A., Mannara, F., et al. (2024) · Brain · doi:10.1093/brain/awae410 · Cited by 38
Self-citationAnti-NMDA Receptor Encephalitis Presenting with Focal Non-Convulsive Status Epilepticus in a Child
Goldberg, E. M., Taub, K., Kessler, S. K., & Abend, N. S. (2011) · Neuropediatrics · doi:10.1055/s-0031-1295408 · Cited by 38
Kaplan, P. W., Rossetti, A. O., Kaplan, E. H., & Wieser, H. G. (2012) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2011.11.029 · Cited by 38
Anti-NMDA receptor encephalitis presenting with total insomnia — A case report
Marques, I. B., Teotónio, R., Cunha, C., Bento, C., & Sales, F. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.10.034 · Cited by 38
Zhou, X., Nie, Z., Roberts, A. J., Zhang, D., Sebat, J. L., Malhotra, D., Kelsoe, J. R., & Geyer, M. A. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq298 · Cited by 38
Anti– N -Methyl- D -Aspartate (NMDA) Receptor Encephalitis
Scott, O., Richer, L. P., Forbes, K., Sonnenberg, L. K., Currie, A., Eliyashevska, M., & Goez, H. (2013) · Journal of Child Neurology · doi:10.1177/0883073813501875 · Cited by 39
More than memory impairment in voltage‐gated potassium channel complex encephalopathy
Bettcher, B. M., Gelfand, J. M., Irani, S. R., Neuhaus, J. M., Forner, S. A., Hess, C. P., & Geschwind, M. D. (2014) · European Journal of Neurology · doi:10.1111/ene.12482 · Cited by 38
Freundt-Revilla, J., Maiolini, A., Carlson, R., Beyerbach, M., Rentmeister, K., Flegel, T., Fischer, A., & Tipold, A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0784-3 · Cited by 38
Wang, B., Wang, C.-J., Zeng, Z., Yang, Y., & Guo, S. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.04.007 · Cited by 38
Neurobiology of autoimmune encephalitis
Fukata, M., Yokoi, N., & Fukata, Y. (2017) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2017.07.012 · Cited by 38
An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDAR encephalitis
Zhou, J., Tan, W., Tan, S. E., Hu, J., Chen, Z., & Wang, K. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.03.019 · Cited by 38
Huang, Q., Ma, M., Wei, X., Liao, Y., Qi, H., Wu, Y., & Wu, Y. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2018.01136 · Cited by 38
Li, J., Gu, Y., An, H., Zhou, Z., Dong, Z., Wang, Z., Wen, Z., Shen, H., Wang, Q., & Wang, H. (2019) · Brain and Behavior · doi:10.1002/brb3.1354 · Cited by 38
NMDA-receptor encephalitis in Denmark from 2009 to 2019: a national cohort study
Nissen, M. S., Ørvik, M. S., Nilsson, A. C., Ryding, M., Lydolph, M. C., & Blaabjerg, M. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10738-9 · Cited by 39
Treatment of Refractory Convulsive Status Epilepticus in Children: Other Therapies
Wheless, J. W. (2010) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2010.06.007 · Cited by 38
Autoimmunity in psychotic disorders. Where we stand, challenges and opportunities
Mané-Damas, M., Hoffmann, C., Zong, S., Tan, A., Molenaar, P. C., Losen, M. H., & Martínez‐Martínez, P. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102348 · Cited by 38
Acute psychiatric illness in a young woman: an unusual form of encephalitis
Parratt, K. L., Allan, M., Lewis, S. J. G., Dalmau, J. O., Halmagyi, G. M., & Spies, J. M. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02787.x · Cited by 37
Self-citationThe Rehabilitation of Children with Anti–N-methyl-D-aspartate–Receptor Encephalitis
Houtrow, A. J., Bhandal, M., Pratini, N. R., Davidson, L. T., & Neufeld, J. A. (2012) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0b013e3182465da6 · Cited by 37
Reversible paraneoplastic encephalitis in three patients with ovarian neoplasms
Tanyi, J. L., Marsh, E. B., Dalmau, J. O., & Chu, C. (2012) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/j.1600-0412.2011.01365.x · Cited by 37
Self-citationClinical analysis on anti-N-methyl-D-aspartate receptor encephalitis cases: Chinese experience.
Huang, X., Fan, C., Wu, J., Ye, J., Zhan, S., Song, H., Liu, A., Su, Y., & Jia, J. (2015) · PubMed Central · Cited by 37
Sachs, J. R., Zapadka, M. E., Popli, G., & Burdette, J. H. (2017) · Radiology Case Reports · doi:10.1016/j.radcr.2017.06.004 · Cited by 37
Principles and approaches to the treatment of immune-mediated movement disorders
Mohammad, S. S., & Dale, R. C. (2017) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2017.11.010 · Cited by 37
Gurrera, R. J. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12821 · Cited by 37
Fominykh, V., Brylev, L., Gaskin, V., Лузин, Р. В., Yakovlev, A. A., Komoltsev, I. G., Belousova, I., Рослякова, А. А., Guekht, A. B., & Gulyaeva, N. V. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00452-x · Cited by 37
Ding, J., Li, X., & Tian, Z. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.711376 · Cited by 37
Autoimmune and Paraneoplastic Chorea: A Review of the Literature
Kyle, K., Bordelon, Y. M., Venna, N., & Linnoila, J. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.829076 · Cited by 37
Seizure Semiology in Antibody-Associated Autoimmune Encephalitis
Kaaden, T., Madlener, M., Angstwurm, K., Bien, C. G., Bogarin, Y., Doppler, K., Finke, A., Gerner, S. T., Reimann, G., Häusler, M., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200034 · Cited by 37
Busse, S., Brix, B., Kunschmann, R., Bogerts, B., Stoecker, W., & Busse, M. (2014) · Neuroscience Research · doi:10.1016/j.neures.2014.06.002 · Cited by 39
Psychiatric phenomena as initial manifestation of encephalitis by anti‐NMDAR antibodies
Maat, P., de Graaff, E., van Beveren, N. J. M., Hulsenboom, E., Verdijk, R. M., Koorengevel, K. M., VanDuijn, M. M., Hooijkaas, H., Hoogenraad, C. C., & Smitt, P. A. E. S. (2012) · Acta Neuropsychiatrica · doi:10.1111/acn.12013 · Cited by 37
Encephalopathy in children: an approach to assessment and management
Davies, E., Connolly, D. J. A., & Mordekar, S. (2011) · Archives of Disease in Childhood · doi:10.1136/adc.2011.300998 · Cited by 37
CSF IgA NMDAR antibodies are potential biomarkers for teratomas in anti-NMDAR encephalitis
Desestret, V., Chefdeville, A., Viaccoz, A., Bost, C., Ducray, F., Picard, G., Rogemond, V., Chaffois, M.-O., Blanc, C., Bardel, C., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000166 · Cited by 37
The growing spectrum of antibody-associated inflammatory brain diseases in children
Bigi, S., Hladio, M., Twilt, M., Dalmau, J. O., & Benseler, S. M. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000092 · Cited by 37
Self-citationCanadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults
Hahn, C., Budhram, A., Alikhani, K., Alohaly, N., Beecher, G., Blevins, G., Brooks, J., Carruthers, R. L., Comtois, J., Cowan, J., et al. (2024) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2024.16 · Cited by 36
Varley, J. A., Vincent, A. C., & Irani, S. R. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7600-8 · Cited by 36
Extreme delta brush guides to the diagnosis of anti-NMDAR encephalitis
Wang, J., Wang, K., Wu, D., Liang, H. Y., Zheng, X.-N., & Luo, B. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.04.009 · Cited by 36
Autoimmune Channelopathies of the Nervous System
Kleopa, K. A. (2011) · Current Neuropharmacology · doi:10.2174/157015911796557966 · Cited by 36
Brenton, J. N., Kim, J. P., & Schwartz, R. H. (2016) · Journal of Child Neurology · doi:10.1177/0883073816643406 · Cited by 36
Risk Factors for Intensive Care Unit Admission in Patients with Autoimmune Encephalitis
Harutyunyan, G., Hauer, L., Dünser, M. W., Moser, T., Pikija, S., Leitinger, M., Novak, H. F., Aichhorn, W., Trinka, E., & Sellner, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00835 · Cited by 36
Initial clinical presentation of young children with N-methyl- d -aspartate receptor encephalitis
Favier, M., Joubert, B., Picard, G., Rogemond, V., Thomas, L., Rheims, S., Bailhache, M., Villega, F., Pedespan, J., Berzero, G., et al. (2017) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2017.12.014 · Cited by 36
Yang, S., Zhang, X., Mei, F., Tang, J., Liao, H., & Tan, L. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6329 · Cited by 36
Anti-NMDA receptor encephalitis: a case study and illness overview
Ford, B., McDonald, A., & Srinivasan, S. (2019) · Drugs in Context · doi:10.7573/dic.212589 · Cited by 38
Qu, X.-P., Vidaurre, J. A., Peng, X., Jiang, L., Zhong, M., & Hu, Y. (2019) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2019.11.011 · Cited by 36
Self-citationNeurological complications of pediatric cancer
Armstrong, C., & Sun, L. R. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09847-0 · Cited by 36
Caballero, J. L., Pacchiarotti, I., Murru, A., Valentí, M., Colom, F., Benach, B., Pérez, V., Dalmau, J. O., & Vieta, E. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.012 · Cited by 35
Self-citationGastaldi, V. D., Wilke, J. B. H., Weidinger, C. A., Walter, C., Barnkothe, N., Teegen, B., Luessi, F., STÖCKER, W., Lühder, F., Begemann, M., et al. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.10.016 · Cited by 36
Punja, M., Pomerleau, A. C., Devlin, J. J., Morgan, B., Schier, J. G., & Schwartz, M. D. (2013) · Clinical Toxicology · doi:10.3109/15563650.2013.829235 · Cited by 36
Anti-NMDA receptor encephalitis with the initial presentation of psychotic mania
Kuo, Y. L., Tsai, H. F., Lai, M. C., Lin, C. H., & Yang, Y. K. (2012) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2011.10.006 · Cited by 37
Self-citationAutoimmune Movement Disorders: a Clinical and Laboratory Approach
Honorat, J. A., & McKeon, A. B. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0709-2 · Cited by 36
Braczkowski, M., Soszyński, D., Sierakowska, A., Braczkowski, R., Kufel, K. M., & Labuz-Roszak, B. M. (2023) · Diagnostics · doi:10.3390/diagnostics13152589 · Cited by 35
Morgan, A., Li, Y., Thompson, N. R., Milinovich, A., Abbatemarco, J., Cohen, J. A., Ontaneda, D., Punia, V., Rae-Grant, A. D., Galioto, R., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000208019 · Cited by 35
Metadata
- Authors
- Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., Dessain, S. K., Rosenfeld, M. R., Balice-Gordon, R., & Lynch, D. R.
- Affiliations
- University of Pennsylvania (US)
- Lankenau Institute for Medical Research (US)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Dalmau, Josep
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2008-12
- Volume
- 7
- Issue
- 12
- Pages
- 1091-1098
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC2607118
- OpenAlex
- W2146199022
- Semantic Scholar
- dd855374110d7c7789974ad4472f335d53b94cd9
- Cited by
- 3,488
- References
- 35
- Citations by year
- 2026: 117 · 2025: 130 · 2024: 170 · 2023: 140 · 2022: 198 · 2021: 239 · 2020: 233 · 2019: 525 · 2018: 213 · 2017: 207 · 2016: 227 · 2015: 196 · 2014: 182 · 2013: 196 · 2012: 169
- FWCI
- 72.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (F31MH083395, R56MH057683, R01MH057683, R21 MH057683)
- National Cancer Institute (R01CA089054, R56CA089054, R01CA107192)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Clinical Neurology › Myasthenia Gravis and Thymoma
- Keywords
- anti-NMDA receptor encephalitis, NMDA receptor antibodies, autoimmune encephalitis, ovarian teratoma, psychiatric symptoms, seizures, dyskinesia, autonomic instability, hypoventilation, antibody epitopes, cancer immunotherapy
- MeSH terms
- Adolescent, Adult, Aged, Animals, Epitopes, Autoantibodies, Autoantigens, Brain, Cell Line, Cells, Cultured, Child, Child, Preschool, Encephalitis, Epilepsy, Female, Humans, Male, Middle Aged, Ovarian Neoplasms, Teratoma, Receptors, N-Methyl-D-Aspartate, Neurocognitive Disorders, Autoimmune Diseases of the Nervous System, Paraneoplastic Syndromes, Nervous System, Protein Subunits, Rats, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
